Ronald Williams - Johnson Johnson Independent Director

JNJ Stock  EUR 143.80  1.60  1.10%   

Director

Mr. Ronald A. Williams is an Independent Director of the Company. He served as Chairman and Chief Executive Officer of Aetna Inc. from 2006 to 2010, and as Chairman from 2010 until his retirement in April 2011. He is also an advisor to the private equity firm, Clayton, Dubilier Rice, LLC. In addition, Mr. Williams serves on the boards of MIT Corporationrationration, Peterson Institute for International Economics, the Advisory Board of Peterson Center on Healthcare and is Vice Chairman of the Board of Trustees of The Conference Board. Previously, Mr. Williams served on President Obama Management Advisory Board from 2011 to January 2017, as Chairman of the Council for Affordable Quality Healthcare from 2007 to 2010, and as Vice Chairman of The Business Council from 2008 to 2010. since 2011.
Age 68
Tenure 13 years
Phone732 524 0400
Webhttps://www.jnj.com
Williams served as Chairman and Chief Executive Officer of Aetna Inc. from 2006 to 2010, and as Chairman from 2010 until his retirement in April 2011. He is also an advisor to the private equity firm, Clayton, Dubilier & Rice, LLC. In addition, Mr. Williams also serves on the boards of MIT Corporationrationrationration, Peterson Institute for International Economics, the Advisory Board of Peterson Center on Healthcare and is Vice Chairman of the Board of Trustees of The Conference Board. Previously, Mr. Williams served on President Obama Management Advisory Board from 2011 to January 2017, as Chairman of the Council for Affordable Quality Healthcare from 2007 to 2010, and Vice Chairman of The Business Council from 2008 to 2010.

Ronald Williams Latest Insider Activity

Tracking and analyzing the buying and selling activities of Ronald Williams against Johnson Johnson stock is an integral part of due diligence when investing in Johnson Johnson. Ronald Williams insider activity provides valuable insight into whether Johnson Johnson is net buyers or sellers over its current business cycle. Note, Johnson Johnson insiders must abide by specific rules, including filing SEC forms every time they buy or sell Johnson Johnson'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Johnson Johnson Management Efficiency

The company has return on total asset (ROA) of 0.0871 % which means that it generated a profit of $0.0871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2379 %, meaning that it generated $0.2379 on every $100 dollars invested by stockholders. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 26.89 B in total debt with debt to equity ratio (D/E) of 0.48, which is about average as compared to similar companies. Johnson Johnson has a current ratio of 1.36, which is within standard range for the sector. Debt can assist Johnson Johnson until it has trouble settling it off, either with new capital or with free cash flow. So, Johnson Johnson's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Johnson Johnson sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Johnson to invest in growth at high rates of return. When we think about Johnson Johnson's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Michael MontgomeryNMI Holdings
62
James JonesNMI Holdings
69
James OzanneNMI Holdings
74
Richard BradeenSuperior Plus Corp
61
Patrick GottschalkSuperior Plus Corp
54
James ArestiaNorAm Drilling AS
N/A
Randall FindlaySuperior Plus Corp
67
Steven ScheidNMI Holdings
64
Mary JordanSuperior Plus Corp
58
Craig JacobsonNorAm Drilling AS
65
David SmithSuperior Plus Corp
59
Peter MurphyNorAm Drilling AS
55
Laura WalkerNorAm Drilling AS
60
Eugene BissellSuperior Plus Corp
64
Douglas HarrisonSuperior Plus Corp
58
Walentin MiroshSuperior Plus Corp
71
Peter KernNorAm Drilling AS
50
Ross LevinsohnNorAm Drilling AS
54
Michael EmblerNMI Holdings
53
Regina MuehlhauserNMI Holdings
69
Catherine BestSuperior Plus Corp
64
Johnson Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. Johnson Johnson was founded in 1886 and is based in New Brunswick, New Jersey. JOHNSON JOHNSON operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 136000 people. Johnson Johnson (JNJ) is traded on Frankfurt Exchange in Germany and employs 152,700 people.

Management Performance

Johnson Johnson Leadership Team

Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dirk Brinckman, Chief Officer
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman of the Board, CEO
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, Vice President General Counsel
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Joseph CPA, Ex CFO
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Director
Sandra Peterson, Group Worldwide Chairman
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Robert Decker, Controller Officer
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
James Swanson, Ex Officer
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Vice President - Investor Relations
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Jessica Moore, VP Relations
Ian Davis, Independent Director
Paulus Stoffels, Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Elizabeth Forminard, Exec Counsel
Dominic Caruso, CFO, Vice President - Finance
Peter Fasolo, Vice President - Global Human Resources
Susan Lindquist, Independent Director

Johnson Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Johnson Stock please use our How to Invest in Johnson Johnson guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Johnson Stock analysis

When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.